Age-Related Macular Degeneration (AMD) is one of the leading causes of severe vision loss and blindness in the adult population, with more than 1.6 million existing cases and approximately 200,000 new cases each year in the U.S. Motility Inc., headed by Dr. Levin, is developing a small protein therapeutic (LD22-4) for treatment of the wet form of AMD as well as diabetic retinopathy. The mode of action of LD22-4 is the inhibition of cell migration and it is a potent inhibitor of blood vessel formation (angiogenesis). Using a various animal models of angiogenesis, including tumor, corneal, and retinal models, LD22-4 has been shown to inhibit new blood vessel growth by as much as 90% and promises to offer a novel approach for the treatment of this debilitating disease.

<< Inflammatory Disorders | New Methods for Drug Development >>